TS Gene Polymorphisms Are Not Good Markers of Response to 5-FU Therapy in Stage III Colon Cancer PatientsReportar como inadecuado

TS Gene Polymorphisms Are Not Good Markers of Response to 5-FU Therapy in Stage III Colon Cancer Patients - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Analytical Cellular Pathology - Volume 33 2010, Issue 1, Pages 1-11

PAMM Laboratory for Pathology, Eindhoven, The Netherlands

Fontys University of Applied Science, Centre for Medical Molecular Diagnostics, Eindhoven, The Netherlands

Comprehensive Cancer Centre South, Eindhoven, The Netherlands

Department of Surgery, Máxima Medical Centre Veldhoven, Veldhoven, The Netherlands

Department of Surgical Oncology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands

Department of Molecular Diagnostics, Catharina Hospital Eindhoven, Eindhoven, The Netherlands

Copyright © 2010 Hindawi Publishing Corporation and the authors. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Aim: Although the predictive and prognostic value of thymidylate synthase TS expression and gene polymorphism in colon cancer has been widely studied, the results are inconclusive probably because of methodological differences. With this study, we aimed to elucidate the role of TS gene polymorphisms genotyping in therapy response in stage III colon carcinoma patients treated with 5-FU adjuvant chemotherapy.

Patients and Methods: 251 patients diagnosed with stage III colon carcinoma treated with surgery followed by 5-FU based adjuvant therapy were selected. The variable number of tandem repeats VNTR and the single nucleotide polymorphism SNP in the 5′-untranslated region of the TS gene were genotyped.

Results: There was a positive association between tumor T stage and the VNTR genotypes p=0.05. In both univariate and multivariate survival analysis no effects of the studied polymorphisms on survival were found. However, there was an association between both polymorphisms and age. Among patients younger than 60 years, the patients homozygous for 2R seemed to have a better overall survival, whereas among the patients older than 67 this longer survival was seen by the carriers of other genotypes.

Conclusion: We conclude that the TS VNTR and SNP do not predict response to 5-FU therapy in patients with stage III colon carcinoma. However, age appears to modify the effects of TS polymorphisms on survival.

Autor: A. Fariña-Sarasqueta, M. J. E. M. Gosens, E. Moerland, I. van Lijnschoten, V. E. P. P. Lemmens, G. D. Slooter, H. J. T. Rutten,

Fuente: https://www.hindawi.com/


Documentos relacionados